As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.
GlobalData on MSN13d
Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlightAs the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.
It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug ...
Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...
UBS lowered the firm’s price target on Amgen (AMGN) to $326 from $335. Amgen reported in-line topline sales for Q3, with most products as ...
Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...
Cantor analysts said they found the bone mineral density changes when reviewing supplemental data that was published along ...
While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on ...
Amgen's acquisition of Horizon Therapeutics has notably contributed to its revenue stream, with Horizon products adding $1.1 billion in sales for the quarter. Despite macroeconomic headwinds ...
Discover how Amgen is achieving a fully automated enterprise through strategic partnerships with Cognizant and UiPath to enhance efficiency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback